Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：1
|
作者：
Cerbone, L. [1 ]
Di Nunno, V. [2 ]
Carril, L. [1 ]
Benchimol-Zouari, A. [1 ]
Flippot, R. [1 ]
Silva, C. Alves Costa [1 ]
Colomba-Blameble, E. [1 ]
Guida, A. [3 ]
Derosa, L. [1 ]
Escudier, B. [1 ]
Albiges, L. [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Osped Bellaria, Oncol Med, Bologna, Italy
[3] Osped Santa Chiara Terni, Med & Traslat Oncol, Terni, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
743P
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [41] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Govindarajan, Ameish
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Chawla, Neal Shiv
    Castro, Daniela V.
    Mercier, Benjamin D.
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Li, Xiaochen
    Pal, Sumanta Kumar
    Tripathi, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [42] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience
    Matrana, Marc Ryan
    Shetty, Aditya V.
    Atkinson, Bradley J.
    Xiao, Lianchun
    Corn, Paul G.
    Millikan, Randall E.
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
    Gruenwald, Viktor
    Merseburger, Axel S.
    ONCOTARGETS AND THERAPY, 2012, 5 : 111 - 117
  • [44] Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).
    Marteau, Florence
    Harrow, Brooke
    McCarthy, Christine
    Wallace, Joel
    Monnette, Alisha
    Wang Yunfei
    Doshi, Gurjyot K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [45] Active surveillance (AS) as potential treatment modality for management of patients (pts) with metastatic renal cell carcinoma (mRCC)?
    Ivanyi, P.
    Eggers, H.
    Seidel, C.
    Ganser, A.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 320 - 320
  • [46] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Lin, X.
    Kalanovic, D.
    McKay, R.
    Perkins, J.
    Simantov, R.
    Choueiri, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S642 - S642
  • [48] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Evaluation of safety, tolerability and activity of Temsirolimus in patients (pts) with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Goebell, P. J.
    Goehler, T.
    Harich, H. -D
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 88 - 88
  • [50] EVALUATION OF SAFETY, TOLERABILITY AND ACTIVITY OF TEMSIROLIMUS IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA (A/MRCC) IN ROUTINE CLINICAL PRACTICE
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Goebell, P. J.
    Goehler, T.
    Harich, H.
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    ANNALS OF ONCOLOGY, 2014, 25
12345